Edwards Lifesciences CorporationEWNYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+24.3%
5Y CAGR+11.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+24.3%/yr
Quarterly compound
5Y CAGR
+11.1%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
1.7x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 17.16% |
| Q3 2025 | 2.51% |
| Q2 2025 | 7.79% |
| Q1 2025 | -5.33% |
| Q4 2024 | 16.73% |
| Q3 2024 | -6.52% |
| Q2 2024 | 5.23% |
| Q1 2024 | 2.83% |
| Q4 2023 | 9.09% |
| Q3 2023 | -6.94% |
| Q2 2023 | -5.94% |
| Q1 2023 | 6.16% |
| Q4 2022 | 8.93% |
| Q3 2022 | -7.75% |
| Q2 2022 | 10.45% |
| Q1 2022 | -12.67% |
| Q4 2021 | 16.45% |
| Q3 2021 | -2.67% |
| Q2 2021 | 13.06% |
| Q1 2021 | -2.30% |
| Q4 2020 | 10.15% |
| Q3 2020 | 11.49% |
| Q2 2020 | -10.63% |
| Q1 2020 | -11.25% |
| Q4 2019 | 13.33% |
| Q3 2019 | -0.71% |
| Q2 2019 | 10.12% |
| Q1 2019 | -2.67% |
| Q4 2018 | 7.13% |
| Q3 2018 | -1.75% |
| Q2 2018 | 7.45% |
| Q1 2018 | -3.96% |
| Q4 2017 | 8.68% |
| Q3 2017 | 0.21% |
| Q2 2017 | 6.37% |
| Q1 2017 | -1.93% |
| Q4 2016 | 1.79% |
| Q3 2016 | 0.31% |
| Q2 2016 | 7.57% |
| Q1 2016 | -4.32% |